Founded in New York City, Owkin, Inc. is a biotech company specializing in predictive analytics through machine learning. Its core mission is to revolutionize drug discovery and development by analyzing complex biomarker patterns in molecular, imaging libraries, and patient datasets. Owkin offers services such as AI-driven drug discovery, target discovery, and diagnostics, focusing on serving pharmaceutical companies globally. Their vision is to harness the power of AI to uncover insights that can lead to more effective treatments and improved patient outcomes.
Notable affiliated people include co-founders Thomas Clozel and Gilles Wainrib. Owkin has attracted significant investment from major players like GV (formerly Google Ventures) and Bpifrance. Key achievements include developing a federated research network that allows secure, collaborative data analysis across institutions without sharing sensitive data. Owkin's impact is evident in its contributions to advancing precision medicine and enhancing the efficiency of pharmaceutical research and development.
